Free Trial

Onconetix (ONCO) Competitors

Onconetix logo
$4.83 +0.60 (+14.18%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$4.76 -0.07 (-1.37%)
As of 07/14/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ONCO vs. TLPH, CLDI, LSB, AEON, ARTL, DWTX, JBIO, KPRX, CLRB, and CHRO

Should you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Talphera (TLPH), Calidi Biotherapeutics (CLDI), LakeShore Biopharma (LSB), AEON Biopharma (AEON), Artelo Biosciences (ARTL), Dogwood Therapeutics (DWTX), Jade Biosciences (JBIO), Kiora Pharmaceuticals (KPRX), Cellectar Biosciences (CLRB), and Chromocell Therapeutics (CHRO). These companies are all part of the "pharmaceutical products" industry.

Onconetix vs. Its Competitors

Talphera (NASDAQ:TLPH) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Talphera has a net margin of 0.00% compared to Onconetix's net margin of -2,913.71%. Talphera's return on equity of -130.28% beat Onconetix's return on equity.

Company Net Margins Return on Equity Return on Assets
TalpheraN/A -130.28% -59.25%
Onconetix -2,913.71%-514.04%-75.82%

In the previous week, Talphera and Talphera both had 1 articles in the media. Talphera's average media sentiment score of 1.89 equaled Onconetix'saverage media sentiment score.

Company Overall Sentiment
Talphera Very Positive
Onconetix Very Positive

37.7% of Talphera shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 3.2% of Talphera shares are owned by insiders. Comparatively, 3.1% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Talphera currently has a consensus price target of $5.00, indicating a potential upside of 955.07%. Given Talphera's stronger consensus rating and higher possible upside, research analysts clearly believe Talphera is more favorable than Onconetix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Talphera
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50
Onconetix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Talphera has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.38, meaning that its share price is 238% more volatile than the S&P 500.

Talphera has higher earnings, but lower revenue than Onconetix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talphera$27K359.87-$13M-$0.45-1.05
Onconetix$2.52M1.02-$58.69MN/AN/A

Summary

Talphera beats Onconetix on 11 of the 13 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONCO vs. The Competition

MetricOnconetixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.56M$2.95B$5.54B$9.14B
Dividend YieldN/A2.43%5.01%4.00%
P/E RatioN/A21.1628.6819.45
Price / Sales1.02184.72374.0179.78
Price / CashN/A41.0524.7227.47
Price / Book0.437.758.255.58
Net Income-$58.69M-$55.05M$3.19B$252.81M
7 Day Performance0.63%9.69%3.60%2.11%
1 Month Performance2.11%13.80%9.60%11.87%
1 Year Performance-99.03%3.55%30.55%16.61%

Onconetix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONCO
Onconetix
0.5693 of 5 stars
$4.83
+14.2%
N/A-99.1%$2.56M$2.52M0.0012Positive News
TLPH
Talphera
2.0081 of 5 stars
$0.47
+1.9%
$5.00
+959.3%
-49.0%$9.66M$27K-1.0519
CLDI
Calidi Biotherapeutics
0.5678 of 5 stars
$0.30
+24.1%
N/A-63.4%$9.47MN/A0.0038Gap Down
High Trading Volume
LSB
LakeShore Biopharma
0.7476 of 5 stars
$1.20
+21.9%
N/A-76.4%$9.26M$80.82M0.00773Gap Down
High Trading Volume
AEON
AEON Biopharma
2.4229 of 5 stars
$0.81
+2.6%
$360.00
+44,235.0%
-99.2%$9.18MN/A4.515
ARTL
Artelo Biosciences
2.6304 of 5 stars
$16.59
+15.9%
$25.00
+50.7%
+138.8%$9.13MN/A-0.935Gap Down
High Trading Volume
DWTX
Dogwood Therapeutics
1.8943 of 5 stars
$4.71
+2.3%
$10.00
+112.5%
N/A$8.99MN/A-0.265
JBIO
Jade Biosciences
2.3075 of 5 stars
$10.42
-0.3%
$14.00
+34.4%
N/A$8.76MN/A-0.1720Analyst Forecast
KPRX
Kiora Pharmaceuticals
3.2118 of 5 stars
$2.87
+2.0%
$10.00
+249.0%
-27.2%$8.72MN/A-0.9910
CLRB
Cellectar Biosciences
2.5635 of 5 stars
$4.82
+0.3%
$375.00
+7,688.2%
-93.4%$8.72MN/A-0.2210Positive News
CHRO
Chromocell Therapeutics
N/A$1.34
+6.3%
N/A-88.3%$8.69MN/A-1.084Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ONCO) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners